About BioNexus Gene Lab Corp - Common stock (BGLC)
Bionexus Gene Lab Corp is a biotechnology company focused on the development and commercialization of innovative genomic solutions and technologies. The company specializes in harnessing the power of genetic research to create advanced diagnostic tools and therapeutic products aimed at improving health outcomes. Through its cutting-edge platforms, Bionexus aims to enhance our understanding of genetic diseases and facilitate precision medicine, thereby contributing to more effective treatments and personalized healthcare solutions. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Investor Action Alert – Undercard Stocks Breaking Out Beneath the Surface of the Mag 7 - While Big Tech’s “Mag 7” continues to dominate headlines, a new wave of high-upside small- and mid-cap stocks is making serious noise—and the time to pay attention is now .
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company (“Fidelion”) today announced the signing of a term sheet for a strategic, cross-equity partnership that the parties are calling a “DeepSeek-class leap” for liquid biopsy cancer monitoring and AI-driven biotechnology. This builds on BGLC’s mission to be a global leader in liquid biopsies, and tumor naïve oncology solutions.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
